We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Sino Biological Logo

Sino Biological

Sino Biological is an international reagent supplier and service provider. The company specializes in recombinant protein production and antibody development. All of Sino Biological's products are independently developed and produced, including recombinant proteins, antibodies and cDNA clones.

Latest Sino Biological Content

Cell therapy.
Product News

InDevR and Sino Biological Team Up To Deliver Multiplexed Analytical Solutions for mRNA Vaccine and Cell & Gene Therapy

Partnership addresses biopharmaceutical industry’s urgent need for improved in-process and QC testing tools for these rapidly evolving application fields.
CD2-CD58 Axis: Targets in Immune Synapse, cancer immunotherapy, autoimmune diseases, immune evasion of tumors, antiviral responses, immune rejection
Product
Advertisement

CD2-CD58 Axis: Targets in Immune Synapse

Click here for further information!
A labelled antibody and a cell.
Product News

FDA-Approved TIVDAK®: Targeting Tissue Factor in Cervical Cancer

On April 29th, the U.S. FDA granted full approval for Seagen Inc.'s TIVDAK® (tisotumab vedotin) targeting tissue factor (TF) for the treatment of patients with recurrent or metastatic cervical cancer who have progressed on or after chemotherapy.
A scientist using an iPad in a lab.
Product News

Sino Biological Finalizes the Acquisition of SignalChem Biotech

Sino Biological, Inc. ("Sino Biological" or the "Company”), has successfully concluded its acquisition of Vancouver-based Canadian biotechnology company SignalChem Biotech Inc.
The Landscape of Cancer Research: Advances in Immuno-oncology
Online Event

The Landscape of Cancer Research: Advances in Immuno-oncology 2024

Key advances will be highlighted across the field of immuno-oncology. Hear a cross-section of experts discuss their research with a focus on basic research and a broad range of established and novel immunotherapeutics.
Antibodies.
Product News

Therapeutic Potential of CD20 X CD3 Bispecific Antibodies

As of March 2024, the FDA has approved three CD20 × CD3 BsAbs: mosunetuzumab (Lunsumio) for relapsed or refractory follicular lymphoma (R/R FL), glofitamab (Columvi) for relapsed or refractory diffuse B cell lymphoma
Cytokines for BEST Cell Culture
Product
Advertisement

BEST-IN-CLASS Cytokines for BEST Cell Culture

Click here for further information!
Cell and Gene Therapy Symposium, March 20-21: Experts discuss cancer immunotherapy, gene vectors, stem cells, and precision oncology
Online Event

Cell and Gene Therapy 2024

On-Demand
Explore cutting-edge cell and gene therapies at our online symposium on March 20–21. Experts will discuss cancer immunotherapy, gene therapy vectors, stem cells, and precision oncology research.
3D Organoid Research Solutions
Product
Advertisement

3D Organoid Research Solutions

Learn More!
MMPs, Architects of Tumor Microenvironment
Product
Advertisement

MMPs: Architects of Tumor Microenvironment

Learn more about MMPs!
Advertisement